ALRT - ALRT STOCK NEWS

ALR Technologies Inc. (ALRT) has announced progress on its migration to Singapore, with the SEC declaring effective its Registration Statement on Form F-4 for its affiliate, ALR Technologies SG Ltd. A prospectus is set to be mailed to stockholders around October 4, 2022, with plans to complete a reincorporation merger soon after. Additionally, a distribution agreement for the GluCurve Pet CGM with a leading animal health company has been postponed to Q4 2022 due to manufacturing delays, although positive feedback on the product remains high.

ALR Technologies SG Pte. Ltd. (OTCQB: ALRT) announced a distribution agreement with a global leader in animal health, with completion expected in September, slightly delayed from late August. This delay is not expected to hinder commercialization, with the first Purchase Order for GluCurve Pet CGM hardware already placed for October delivery. The GluCurve Pet CGM is designed for diabetic pets, featuring a sensor that provides real-time glucose readings. The company is also preparing for key trade shows and establishing connections with veterinary professionals to enhance marketing efforts.

ALR Technologies SG Pte. Ltd (ALRT) announced on August 1, 2022, it received manufacturing approval from Infinovo Medical Co., Ltd. for the GluCurve Pet CGM. The first purchase order is expected to be delivered by October 2022. Due to scheduling delays, both parties agreed to extend the deadline for a binding sales and distribution agreement to August 31, 2022. The GluCurve Pet CGM is the first of its kind for diabetic pets, providing remote glucose monitoring capabilities. ALRT is working on a new agreement with a leading animal health company, with anticipation of not impacting commercialization timelines.

ALR Technologies SG Pte. Ltd. (ALRT) has finalized a manufacturing agreement with Infinovo Medical Co. Ltd. for the production of Continuous Glucose Monitor (CGM) hardware, aimed at the veterinary market. This agreement provides ALRT exclusive global distribution rights for Infinovo's CGM hardware in animal health, with initial deliveries expected in Q4 2022. CEO Sidney Chan emphasized that this milestone supports ALRT's commercialization strategy and profitability goals, with further plans for distribution partnerships in progress. The agreement is contingent on a distribution deal being finalized by July 31, 2022.

ALR Technologies Inc. (ALRT) has announced a Reincorporation Merger Agreement to change its incorporation from Nevada to Singapore. The merger involves a one-for-one share exchange, allowing existing shareholders to maintain their equity ownership in ALRT Singapore. The agreement has obtained board approval and majority shareholder consent, pending further dissemination of an Information Statement and Prospectus. The transition, seen as a strategic move, aims to bolster the company’s global presence, improve accessibility to skilled personnel, and enhance government support for its diabetes management initiatives.

ALR Technologies Inc. (ALRT) announced successful results from a non-inferiority study of its GluCurve Pet CGM, designed for diabetic pets. The study showed that GluCurve was more accurate than leading Blood Glucose Meters for animals 47.8% of the time and had 100% of its readings within ±20% of reference values, compared to 86.9% for the BGM. The average deviation from baseline for GluCurve was 9.7%. The company is now focusing on partnership agreements to launch GluCurve Pet CGM commercially in Q3 2022, addressing an unmet need in veterinary diabetes care.

ALR Technologies Inc. (OTCQB: ALRT) has revealed preliminary findings from the ongoing Non-Inferiority Study of its GluCurve Pet CGM. The results indicate that GluCurve matches the leading veterinary Blood Glucose Meter (BGM) in accuracy, meeting ISO: 15197:2013 standards. GluCurve offers significant advantages by recording blood glucose levels every 3 minutes over 14 days, minimizing stress for pets compared to traditional BGM testing. The company anticipates discussing final study results with a prospective pharmaceutical partner next month, highlighting the potential to establish GluCurve as the standard of care for diabetic pets.

ALR Technologies (ALRT) announced the integration of its GluCurve Pet CGM platform with Infinovo's P3 CGM technology, enhancing diabetes management for pets. The GluCurve app provides real-time glucose data to pet owners and veterinarians, facilitating better insulin dosing and treatment comparisons. A non-inferiority study is set for this month, with commercialization expected in summer 2022, potentially leading ALRT to cash flow positivity. Additionally, ALRT plans to offer the ALRT Diabetes Solution with CGMs for humans by 2023.

ALR Technologies (ALRT) announced a transformative year in 2021 through strategic milestones. Key developments include launching the GluCurve Pet Continuous Glucose Monitor (CGM), expected to generate revenue and positive cash flow in 2022. The company targets a partnership with a pharmaceutical firm by May 2022 and is working towards FDA clearance for a human health CGM by late 2023 or early 2024. ALRT's long-term goal is to list on a major exchange, leveraging interest from institutional investors and enhancing the company's growth strategy.